StockTipsArenaBeta

BUY Lupin Limited — Sumeet Bagadia, Choice Broking

BUYLupin Limited
Lupin share price target & all analyst calls

bySumeet Bagadia, Choice BrokingHorizon: NA (inferred Swing (≤2wk))29 Sept 2026via Zee Business (Live)

Entry₹2,086.3Inferred
Target₹2,150
Total upside +3.05% (call closed)
Stop lossNot given
At expiry₹1,953.613 Oct 2026, 3:30 pm
Expired-6.36%auction close
Follow Sumeet Bagadia for new calls(31% target hit, 439 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 1 active Swing call on LUPINSee 282 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 13 Oct 2026
7 supporting0 opposing
Supports the BUY call (7)

Lupin gets US FDA nod for vitamin K injection with $52 million US market

NewsCnbc-Tv18·8 Oct · 4d ago

(opens in new tab)

Lupin received U.S. FDA approval for its Phytonadione Injectable Emulsion, USP.

BSE · Company Update·8 Oct · 4d ago

(opens in new tab)

Lupin has launched Formoflo-G MDI, the world's first fixed-dose triple combination drug for the management of Chronic Obstructive Pulmonary Disease (COPD).

BSE · Company Update·6 Oct · 1w ago

(opens in new tab)

Lupin Ltd has increased its stake in Multicare Pharmaceuticals Philippines, Inc. (MPPI) through a share buyback, making MPPI a step-down wholly owned subsidiary.

BSE · Company Update·1 Oct · 2w ago

(opens in new tab)

Lupin Ltd has received tentative approval from the U.S. FDA for its Apixaban oral suspension, a generic version of a drug used to reduce the risk of stroke and blood clots.

BSE · Company Update·28 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from Sumeet Bagadia, Choice Broking

Every call and its outcome